Search results for: Kenneth Arrow
Filter search results
Cornerstones of “Fair” Drug Coverage: Appropriate Cost – Sharing and Utilization Management Policies for Pharmaceuticals
1 September 2020
…criteria should not deviate from the FDA label in a manner that would narrow coverage. (3) For drugs deemed to be priced unreasonably, criteria may narrow coverage to the eligibility…
Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
22 June 2022
…is almost double that. Figure 1: Annual numbers of NMES and BLAS approved by FDA’s CDER Source: https://media.nature.com/original/magazine-assets/d41573-021-00002-0/d41573-021-00002-0.pdf 3. CBO relies on a narrow conception of biopharmaceutical innovation The CBO…
Cornerstones of ‘Fair’ Drug Coverage
30 September 2020
…FDA label in a manner that would narrow coverage. (3) For drugs deemed to be priced unreasonably, criteria may narrow coverage to the eligibility criteria from the pivotal trials if…
The UK’s Publicly Funded Vaccines Market
23 November 2010
…data requirements clearer, but adopting the same narrow, NHS-only perspective was considered limiting. Although this may maximise cost-effectiveness, it is not necessarily the most efficient method for the budget of…
Looking Further Afield – What Can Health Economics Learn from the Environmental Economics Approach to Discounting?
1 February 2024
…and Opoku, E.E.O., 2023. Environmental degradation and economic growth: Investigating linkages and potential pathways. Energy Economics, 123, p.106734. 10.1016/j.eneco.2023.106734. Arrow, K., Cropper, M., Gollier, C., Groom, B., Heal, G., Newell,…
Spotlight on OHE: Measuring Preferences, HTA Benchmarking, Value-Based Pricing, and Rationing
13 October 2011
…Regulatory Policy Institute (RPI) Annual Conference, which explored the trade-offs between complexity and simplicity in competition and regulatory policy. He participated in a session with George Yarrow, Chairman of the…
Employer Costs from Respiratory Infections
16 December 2024
Share this: Download publication Helen Hayes Brittany Darrow Lotte Steuten Graham Cookson Amanda Cole Our latest research shows respiratory infections cost UK businesses £44 billion a year. Workplace vaccination programs…
The Importance of Diversity of Supply in Rare Diseases Markets
23 January 2025
Share this: Download publication Matthew Napier Brittany Darrow Matthias Hofer Mikel Berdud Amanda Cole Rare disease medicine markets often rely on single suppliers, increasing the risk of shortages and limiting…
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
…footprint compared to shorter- acting alternatives. Realising the potential value of long-acting therapies is currently hindered by a narrow view of value in health technology assessment (HTA) and variability across…